Lose Weight and Treat Sleep Apnea with SleepBound
The Sleep Wellness Center at Griffin Hospital offers an innovative “Sleep Bound” program to address obstructive sleep apnea and obesity with patient-centered comprehensive care that may include GLP-1 weight-loss medication.
Your Weight May Be Affecting Your Sleep and Overall Health
The U.S. Food and Drug Administration (FDA) approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity when paired with a reduced-calorie diet and increased physical activity. Griffin’s Sleep Bound program will work with patients to develop an individualized treatment plan that could include Zepbound.
Poor sleep is nothing to snooze about. Individuals with sleep apnea are at an increased risk for chronic health conditions, including:
- High blood pressure
- Heart Attacks
- Heart Disease
- Irregular Heart Beat
- Diabetes
- Strokes
Additionally, an untreated sleep disorder has been shown to lead to depression, anxiety, difficulty concentrating and memory loss. All of these mental health conditions can lead to poor work performance and financial insecurity as well as reduced time with family and friends and being able to do your favorite activities.
As a Planetree certified patient-centered hospital, Griffin is committed to offering access to innovative healthcare services and trusted health information in a kind and compassionate manner. Griffin is one of the first hospitals in the state to offer this type of revolutionary treatment for obstructive sleep apnea.
“We see that individuals diagnosed with obesity struggle with sleep apnea and CPAP adherence, leading to daytime fatigue, high blood pressure, and Type 2 diabetes.”
— Sleep Wellness Center at Griffin Hospital Medical Director Dr. Marya Chaisson
Who Qualifies
To qualify for SleepBound, individuals will need to a have:
- A qualifying baseline sleep study (preferably within the last two years)
- Demonstrate moderate to severe sleep apnea
- Meet a certain Body Mass Index (BMI) threshold.
After significant weight loss, participants will repeat their sleep study to re-evaluate the status of their obstructive sleep apnea.
Eligible patients may qualify for Zepbound with insurance authorization. Patient exclusions from the program include current use of other GLP-1 agonist medications, and insulin-dependent diabetes.
Make an Appointment
For more information on how to qualify for Sleep Bound, contact Pulmonary Specialties at 203-732-7573.